Alzheimer's disease There is no evidence that<unk>  or other similar agents alters the course or progression of Alzheimer's disease. Six-to-twelve-month controlled studies have shown modest benefits in cognition or behavior. The UK National Institute for Clinical Excellence (NICE) recommends<unk>  as an option in the management of mild to moderate Alzheimer's disease. The person should, however, be reviewed frequently and if there is no significant benefit it should be stopped. In 2006, the U.S. Food and Drug Administration (FDA) also approved<unk>  for treatment of mild, moderate and severe dementia in Alzheimer's disease. There is a great deal of clinical evidence that shows dropping Aricept from a Dementia patient's treatment lead to a dramatic decline in the patients cognitin. Other * Lewy body dementia: Some studies have shown benefits of<unk>  for the treatment of cognitive and behavioral symptoms in Lewy body dementia. * Traumatic brain injury: Some research suggests an improvement in memory dysfunction in patients with traumatic brain injury with<unk>  use. * Vascular dementia: Studies have shown that<unk>  may improve cognition in patients with vascular dementia but not overall global functioning. * Dementia associated with Parkinson disease: Some evidence suggests that<unk>  can improve cognition, executive function, and global status in Parkinson disease dementia.
Donepezil
Carbidopa/levodopa
Bremelanotide
Adrafinil
Glybuzole
Glysobuzole
Memantine
Rivastigmine